XGN vs. DMTK, PMD, CNTG, BGLC, ENZ, PSNL, FEMY, THTX, NMTC, and VIRX
Should you be buying Exagen stock or one of its competitors? The main competitors of Exagen include DermTech (DMTK), Psychemedics (PMD), Centogene (CNTG), BioNexus Gene Lab (BGLC), Enzo Biochem (ENZ), Personalis (PSNL), Femasys (FEMY), Theratechnologies (THTX), NeuroOne Medical Technologies (NMTC), and Viracta Therapeutics (VIRX). These companies are all part of the "medical" sector.
DermTech (NASDAQ:DMTK) and Exagen (NASDAQ:XGN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, profitability, community ranking, valuation, risk and institutional ownership.
In the previous week, Exagen had 18 more articles in the media than DermTech. MarketBeat recorded 23 mentions for Exagen and 5 mentions for DermTech. DermTech's average media sentiment score of 0.74 beat Exagen's score of -0.13 indicating that Exagen is being referred to more favorably in the news media.
Exagen has a net margin of -34.74% compared to Exagen's net margin of -572.19%. DermTech's return on equity of -75.86% beat Exagen's return on equity.
Exagen has higher revenue and earnings than DermTech. Exagen is trading at a lower price-to-earnings ratio than DermTech, indicating that it is currently the more affordable of the two stocks.
DermTech has a beta of 2.53, indicating that its share price is 153% more volatile than the S&P 500. Comparatively, Exagen has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500.
DermTech presently has a consensus price target of $2.38, suggesting a potential upside of 316.16%. Exagen has a consensus price target of $7.00, suggesting a potential upside of 270.37%. Given Exagen's higher possible upside, equities research analysts plainly believe DermTech is more favorable than Exagen.
DermTech received 26 more outperform votes than Exagen when rated by MarketBeat users. Likewise, 57.50% of users gave DermTech an outperform vote while only 54.05% of users gave Exagen an outperform vote.
20.5% of DermTech shares are owned by institutional investors. Comparatively, 75.3% of Exagen shares are owned by institutional investors. 5.1% of DermTech shares are owned by company insiders. Comparatively, 36.8% of Exagen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Exagen beats DermTech on 12 of the 18 factors compared between the two stocks.
Get Exagen News Delivered to You Automatically
Sign up to receive the latest news and ratings for XGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding XGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
